Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
Study Identifier
192024-041D
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1/Phase 2
Sex
Female & Male
Age
18+ years
Protocol Summary
This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension. At least 3 dose strengths will be evaluated based on internal data review of each cohort. The study was planned to be conducted in 2 stages. Stage 1 was an open-label and Stage 2 was planned to be masked; however only Stage 1 was conducted.
Study Locations
Location
Status
Location
Sall Research Medical Center
Artesia, California, United States, 90701
Status
Not applicable
Location
Shiley Eye Center, Hamilton Glaucoma Center, University of California, San Diego
La Jolla, California, United States, 92093
Status
Not applicable
Location
Doheny Eye Institute
Los Angeles, California, United States, 90033
Status
Not applicable
Location
Martel Eye Medical Group
Rancho Cordova, California, United States, 95670
Status
Not applicable
Location
Shasta Eye Medical Group, Inc.
Redding, California, United States, 96002
Status
Not applicable
Location
Grutzmacher and Lewis, Inc.
Sacramento, California, United States, 95815
Status
Not applicable
Showing {first} - {last} of {total} Results